IGHA1 and IgA glomerulonephritis: BAFF blockade may be less effective in diseases driven by IgA1 autoantibodies, and indeed, there are no reports in the literature of belimumab’s efficacy in IgA nephropathy, which is thought to be principally associated with IgA1 autoantibodies.21